PSMA3-AS1

Across TCGA pan-cancer cohorts, PSMA3-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PSMA3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PSMA3-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PSMA3-AS1 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

LIHC, KIRC, and LUSC are the cancer types where PSMA3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PSMA3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.881	<.001	8	view →
KIRC	All	II,III,IV	−0.311	.001	8	view →
LUSC	All	All	−0.475	<.001	7	view →
KICH	Female	All	−0.876	<.001	6	view →
LUAD	All	II,III,IV	−0.555	.002	6	view →
BRCA	Female	All	−0.308	<.001	4	view →
CHOL	Male	All	+1.576	<.001	3	view →
STAD	All	II,III,IV	+0.456	.026	2	view →
UCEC	All	All	−0.335	.025	2	view →
THCA	All	All	−0.256	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PSMA3-AS1–LIHC

Open the LIHC breakdown →